Your session is about to expire
What is Cytoxan
CyclophosphamideThe Generic name of this drug
Treatment SummaryCyclophosphamide is a medication that is used to treat certain types of cancer, such as lymphoma and leukemia. It is a precursor drug which needs to be activated in the liver in order to become effective and it has side effects such as alopecia (hair loss), sterility, birth defects, mutations, and cancer. It has also been used to defleec sheep.
Cyclophosphamideis the brand name
Cytoxan Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Cyclophosphamide
Cyclophosphamide
1959
75
Approved as Treatment by the FDA
Cyclophosphamide, otherwise called Cyclophosphamide, is approved by the FDA for 41 uses like Retinoblastoma and Glomerulonephritis .Retinoblastoma
Glomerulonephritis
Acute Myeloid Leukemia (AML)
Breast Cancer
Chronic Lymphocytic Leukemia (CLL)
Lung Cancers
histiocytic lymphoma
Leukemia, Myelocytic, Acute
Non-Hodgkin's Lymphoma (NHL)
mixed-cell type lymphoma
Chronic Myeloid Leukemia (CML)
Adenocarcinoma of the Ovaries
Acute Lymphoblastic Leukemia (ALL)
Disseminated Neuroblastoma
Nephrotic syndrome with lesion of minimal change glomerulonephritis
Burkitt Lymphoma (BL)
Lymphocytic Lymphomas
Hodgkins Disease (HD)
Acute monocytic leukemia
Malignant Lymphomas
Multiple Myeloma (MM)
Hodgkin Disease
failure with corticosteroid therapy
Lung Cancer
Acute Myeloid Leukemia
Acute Coryza
Erythema Induratum
Neuroblastoma
Lymphoma, Non-Hodgkin
Acute Lymphoblastic Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Myeloid, Acute
Breast Cancer
Non-Hodgkin's Lymphoma
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lymphoma, Non-Hodgkin
Adenocarcinoma
Multiple Myeloma
Lymphoma, Large B-Cell, Diffuse
Chronic Lymphocytic Leukemia
Retinoblastoma
Effectiveness
How Cytoxan Affects PatientsCyclophosphamide is a cancer treatment drug that belongs to a group called alkylating agents. These drugs work by attaching small molecules called alkyl groups to certain parts of the DNA in cancer cells. This makes it hard for the cells to replicate, and eventually the cells die. Alkylating agents are not specific to any stage of the cell cycle and can also disrupt normal DNA function, causing cells to die.
How Cytoxan works in the bodyAlkylating agents work by interfering with DNA and RNA. They attach alkyl groups to DNA bases, which damages the DNA and prevents it from being copied or transcribed. They also cause cross-links to form between atoms in the DNA, which also stops it from being copied or transcribed. Finally, they cause mispairing of the nucleotides which leads to mutations.
When to interrupt dosage
The prescribed dosage of Cytoxan depends on the diagnosed affliction, including Lymphoma, Glomerulonephritis and Leukemia, Myelocytic, Acute. The amount of dosage varies in line with the technique of delivery (e.g. Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular or Powder, for solution - Intravenous) referenced in the table beneath.Condition
Dosage
Administration
Breast Cancer
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Leukemia, Lymphocytic, Chronic, B-Cell
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Hodgkin Disease
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Retinoblastoma
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Lymphoma, Large B-Cell, Diffuse
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Lymphoma, Non-Hodgkin
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Acute Myeloid Leukemia
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Acute Lymphoblastic Leukemia
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Lung Cancer
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
failure with corticosteroid therapy
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Lymphoma, Non-Hodgkin
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Erythema Induratum
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Chronic Lymphocytic Leukemia
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Multiple Sclerosis
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Glomerulonephritis
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Acute Coryza
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Lupus
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Leukemia, Myeloid, Acute
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Neuroblastoma
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Warnings
Cytoxan ContraindicationsCondition
Risk Level
Notes
severely depressed bone marrow function
Do Not Combine
Urinary Bladder Neck Obstruction
Do Not Combine
Common Cytoxan Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Cyclophosphamide.
Abetimus
Major
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Abetimus.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Cyclophosphamide.
Cytoxan Toxicity & Overdose RiskCommon side effects of the drug include a decrease in white blood cells, high fever, hair loss, nausea, vomiting, and diarrhea.
Cytoxan Novel Uses: Which Conditions Have a Clinical Trial Featuring Cytoxan?
There are 1165 active clinical trials investigating the potential of Cytoxan to alleviate Breast Cancer, Lymphocytic Lymphomas and Multiple Myeloma.Condition
Clinical Trials
Trial Phases
Non-Hodgkin's Lymphoma
124 Actively Recruiting
Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3, Phase 4
Multiple Sclerosis
120 Actively Recruiting
Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1
Acute Myeloid Leukemia
274 Actively Recruiting
Phase 2, Phase 1, Phase 3, Phase 4, Not Applicable, Early Phase 1
Hodgkin Disease
3 Actively Recruiting
Not Applicable, Phase 1
Multiple Myeloma
6 Actively Recruiting
Phase 1, Phase 2
Lung Cancer
178 Actively Recruiting
Phase 3, Not Applicable, Phase 1, Phase 2, Early Phase 1
Lymphoma, Large B-Cell, Diffuse
0 Actively Recruiting
Chronic Lymphocytic Leukemia
145 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4
Acute Lymphoblastic Leukemia
119 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4
Adenocarcinoma
2 Actively Recruiting
Phase 2, Phase 1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
0 Actively Recruiting
Neuroblastoma
0 Actively Recruiting
Glomerulonephritis
1 Actively Recruiting
Phase 3
Leukemia, Myeloid, Acute
0 Actively Recruiting
Erythema Induratum
0 Actively Recruiting
failure with corticosteroid therapy
0 Actively Recruiting
Retinoblastoma
5 Actively Recruiting
Phase 2, Not Applicable, Phase 1
Lymphoma, Non-Hodgkin
2 Actively Recruiting
Phase 1
Breast Cancer
26 Actively Recruiting
Phase 2, Phase 1, Not Applicable
Lupus
6 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Cytoxan Reviews: What are patients saying about Cytoxan?
5Patient Review
1/24/2013 I was surprised that I never got sick while using this medication, especially since I expected to. It was really easy to take, which is great.
5Patient Review
10/11/2011 This treatment completely removed my overall body pain.
5Patient Review
7/30/2010 I did not enjoy the experience.
5Patient Review
8/8/2010 I was diagnosed with a rare condition called Vasculitis PAN Nodosa in October 2009, and have been taking the medication Cytoxan since. The dose was just increased to 100 mg., and will eventually be increased to 150 mg. I'm just starting to lose my hair, and am concerned about potential side effects.
4.3Patient Review
3/30/2010Patient Q&A Section about cytoxan
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What kind of chemo is Cytoxan?
"In some cases, health care professionals may use the trade name Cytoxan or Neosar when referring to the generic drug name cyclophosphamide. Cyclophosphamide is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug."
Answered by AI
What is Cytoxan used for?
"Cyclophosphamide is a chemotherapy drug used to treat various types of cancer by slowing or stopping cell growth, and also by decreasing the immune system's response to various diseases."
Answered by AI
What are long term side effects of Cytoxan?
"- Long-term side effects of the cancer drug cyclophosphamide include bladder damage and cancer, and bone marrow failure. Bladder cancer is a known risk, and can occur 10-15 years after the drug was given."
Answered by AI
Is Cytoxan the Red Devil?
"I have completed my last round of treatments involving the drugs Adriamycin and Cytoxan, which are often referred to by cancer patients as A/C. In the world of cancer treatment, Adriamycin is often called the “Red Devil,” both for its bright, red color and its nasty side effects."
Answered by AI
Clinical Trials for Cytoxan
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.